

Actelion's Finance

Actelion's financial performance for the first half of 2010


Summary

On 20 July 2010, Actelion announced its financial results for the first half 2010. With total net revenues of CHF 1,024.9 million (H1 2009: CHF 855.2 m) and operating expenses of CHF 698.2 million (H1 2009: CHF 612.4 m), the company reported a first half 2010 operating profit of CHF 326.6 million (H1 2009: CHF 242.9 m).

For the same period, Actelion reported a Non-GAAP EBIT of CHF 405.1 million, an increase of 33 percent compared to the first half of 2009. In local currencies, Non-GAAP EBIT increased by 39 percent. Adjusted (non-US GAAP) diluted earnings per share for the first half 2010 were CHF 2.74, compared to CHF 2.31 during the same period last year.

On a US GAAP basis, net profit for the first half 2010 was CHF 254.2 million (H1 2009: CHF 218.4 m). Fully diluted earnings per share (EPS) on a US GAAP basis for the same period were CHF 2.10, compared to CHF 1.79 for the first half 2009.


Net revenues



During the first half 2010, Actelion's total net revenues increased by 20 percent to CHF 1,024.9 million (H1 2009: CHF 855.2 m). In local currencies, total net revenues increased by 23 percent compared to the same period last year.

Contract revenues for the first half of 2010 amounted to CHF 91.7 million (H1 2009: CHF 32.0 m).

Operating expenses



* Q4 2009 operating expenses include litigation settlement of CHF 93.7m.


During first half 2010, operating expenses were CHF 698.2 million (H1 2009: CHF 612.4 m).

During the same period, research and development expenses increased by 11 percent to CHF 233.2 million (H1 2009: CHF 209.6 m).

Selling, general and administrative expenses for the first half of 2010 amounted to CHF 342.6 million (H1 2009: CHF 299.6 m), an increase of 14 percent.

Actelion Pharmaceuticals Ltd is a global biopharmaceutical company headquartered in Allschwil/Basel, Switzerland. Actelion concentrates on discovering, developing and marketing innovative drugs for high unmet medical needs. The company is quoted on the SIX Swiss Exchange (tickersymbol: ATLN).


Operating income



* Q4 2009 operating expenses include litigation settlement of CHF 93.7m

Actelion's operating profit for the first half of 2010 was CHF 326.6 million (H1 2009: CHF 242.9 m).


Net income



* Q4 2009 operating expenses include litigation settlement of CHF 93.7m

The net profit of CHF 254.2 million (H1 2009: CHF 218.4 m) for the first half of 2010 includes interest income of CHF 1.5 million, predominantly non-cash interest expense of CHF 3.6 million, non-cash interest and amortization charges on the Convertible Bond of CHF 9.2 million, foreign currency losses of CHF 30.2 million and an income tax expense of CHF 31.0 million.

Non-GAAP EBIT



For the first half of 2010, Actelion reported a Non-GAAP EBIT of CHF 405.1 million, an increase of 33 percent compared to the previous year. In local currencies, Non-GAAP EBIT increased by 39 percent. Adjusted (non-US GAAP) diluted earnings per share for the first half 2010 were CHF 2.74, compared to CHF 2.31 during the same period last year.

The Non-GAAP Operating Income excludes charges such as In-Process R&D, charges related to employee stock options under FAS 123R, non-cash depreciation and amortization charges as well as other one-off items which would distort comparative analysis.

Balance sheet

Total assets of Actelion at 30 June, were CHF 2.7 billion.

Financial overview

In CHF million	Results HY 2010	Results HY 2009	in %
Net Revenues	1,024.9	855.2	20
Operating Expenses	698.2	612.4	14
Operating Income	326.6	242.9	34
Non-GAAP EBIT	405.1	304.8	33
Net Income	254.2	218.4	16
Diluted EPS in CHF	2.10	1.79	17
No of shares in calculation	121.314m	122.340m	

The full financial statements can be found on <http://www.actelion.com>.

Share price development over 12 months



Stock charting tools available at www.actelion.com

Actelion Ltd – shares at a glance

The registered shares of Actelion Ltd were first listed on the SWX New Market on April 6, 2000 (symbol: ATLN). A total of 1,000,000 primary shares were placed at the company's Initial Public Offering (IPO), at a price of CHF 260 per share, raising CHF 246.6 million.

On 22 November 2006, Actelion Finance SCA, Luxembourg issued CHF 460 million of senior convertible bonds due 2011 unconditionally and irrevocably guaranteed by Actelion Ltd, Allschwil, Switzerland. The bonds have a coupon of zero percent and an annual yield to maturity of zero percent. The conversion price is CHF 54.17. On or after 30 June 2007 and until the 30th trading day prior to the maturity date on 22 November 2011, each Bond in the denomination of CHF 5,000 is convertible free of charge into cash up to the principal amount and any conversion value above the principal amount may be settled, at the option of Actelion, into cash or Shares or a combination thereof. The issue price was set at 100% and the redemption price at 100%. The Bonds are non-callable for life.

On 18 January 2007, Actelion exercised its right to call for an early redemption of the Senior Unsecured Zero Coupon Convertible Bonds due 15 October 2008 issued by Actelion Finance SCA, Luxembourg on 1 October 2003. The redemption date was 19 February 2007. The bonds were fully converted and 937,068 shares were issued.

On 8 July 2008, the Management Committee of the SIX Swiss Exchange decided to add Actelion shares (ATLN, CH0010532478) to the Swiss Market Index SMI®. Actelion shares have traded as part of the SMI since 22nd September 2008.

Actelion Ltd is part of the following indices: SMI, SPI, SLI, SPIMLC, SPI20, SPISMC, SXXP, SXDP, SBC100, SNSPIX, SMHCAX, SLDI, SXI LIFE SCIENCES and SXI Bio+Medtech. Actelion is traded under the following symbols: Reuters: ATLN.S/ Bloomberg ATLN.

Key share data

Shares outstanding as of 30.06.2010:	129.3 million
Closing share price as of 30.06.2010:	CHF 40.50
Market capitalization as of 30.06.2010:	CHF 5.2 billion
52 week high:	CHF 65.10
52 week low:	CHF 40.00
YTD price change:	-29%
Average daily volume:	0.7 million
Free float:	92.03%

Shareholdings as of 30.06.2010:

Number of registered shareholders: 11,711

Major shareholders as per 30.06.2010

Management & Directors	> 5%
BB Biotech	> 5%
Actelion Ltd	> 5%
Rudolf Maag	> 3%

Disclaimer:

This fact sheet has the sole purpose to provide members of the public with general information about the activities of Actelion Ltd and its associated companies. The forward-looking statements in this fact sheet are based on current expectations and belief of company management, which are subject to numerous risks and uncertainties.

Latest update: June 2010

Actelion Pharmaceuticals Ltd | Gewerbestrasse 16 | CH-4123 Allschwil | Switzerland
e-mail investor.relations@actelion.com | Investor Relations phone +41 61 565 62 62 |
fax +41 61 565 65 07 | www.actelion.com